Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing.

Keating, Paula E; Hock, Barry D; Smith, Stewart M; Chin, Paul K L; O'Donnell, John L; Barclay, Murray L

Keating, Paula E; Hock, Barry D; Smith, Stewart M; Chin, Paul K L; O'Donnell, John L; Barclay, Murray L.

Afiliación

Keating PE; Immunology Section, Canterbury Health Laboratories, Christchurch, New Zealand.
Hock BD; Department of Haematology, University of Otago, Christchurch, New Zealand.
Smith SM; Immunology Section, Canterbury Health Laboratories, Christchurch, New Zealand.
Chin PKL; Department of Medicine, University of Otago, Christchurch, New Zealand.
O'Donnell JL; Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand.
Barclay ML; Immunology Section, Canterbury Health Laboratories, Christchurch, New Zealand.

Intern Med J ; 53(11): 2123-2127, 2023 Nov.

Article en En | MEDLINE | ID: mdl-37997271

Asunto(s)

Adalimumab; Infliximab; Humanos; Adalimumab/uso terapéutico; Monitoreo de Drogas/métodos; Infliximab/uso terapéutico; Nueva Zelanda; Laboratorios

Palabras clave

adalimumab; antidrug antibody; inflammatory bowel disease; infliximab; therapeutic drug monitoring

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adalimumab / Infliximab Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: Intern Med J Asunto de la revista: MEDICINA INTERNA Año: 2023 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Australia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google